Ponatinib vs. asciminib in post–second-generation tyrosine kinase inhibitor therapy for chronic-phase chronic myeloid leukemia: a matching-adjusted indirect comparison by Valentin Garcia-Gutierrez, Fei Huang, Ajibade Ashaye, Mehul Dalal, Victor Laliman-Khara, Massimo Breccia, Megan Rutherford, Hoora Moradian, Petros Patos, Elias Joseph Jabbour

Get full text